Reshma Kewalramani - Aug 15, 2022 Form 4 Insider Report for VERTEX PHARMACEUTICALS INC / MA (VRTX)

Role
CEO & President, Director
Signature
/s/ Joy Liu, Attorney-in-Fact
Stock symbol
VRTX
Transactions as of
Aug 15, 2022
Transactions value $
-$3,565,846
Form type
4
Date filed
8/17/2022, 05:40 PM
Previous filing
Jul 21, 2022
Next filing
Nov 10, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VRTX Common Stock Sale -$3.57M -11.7K -10.5% $305.06 99.6K Aug 15, 2022 Direct F1, F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Transaction made pursuant to Dr. Kewalramani's company approved trading plan under Rule 10b5-1.
F2 Dr. Kewalramani undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
F3 Open market sales reported on this line occurred at a weighted average price of $305.06 (range $305.00 to $305.22).